Market Place
Sourcing Support
Roche scrutinized by UK watchdog over `misleading` Rozlytrek promotional website
21 Sep 2023 //
ENDPTS
FoundationOne Liquid CDx Receives FDA Approval for entrectinib
04 Jan 2023 //
BUSINESSWIRE
Roche`s entrectinib gets FDA nod for Foundation Medicine`s companion diagnostic
10 Jun 2022 //
ENDPTS
Chugai Obtains Approval of FoundationOne CDx Cancer Genomic Profile Rozlytrek
01 Oct 2020 //
PRESS RELEASE
Roche’s Rozlytrek gets EC approval to treat solid tumours and NSCLC
04 Aug 2020 //
PHARMACEUTICAL-TECHNOLOGY
NICE to recommend Roche cancer treatment
26 Jun 2020 //
PHARMAFILE
NICE backs Rozlytrek for subset of NSCLC patients
15 Jun 2020 //
PHARMATIMES
EMA committee recommends conditional marketing approval for Roche’s Rozlytrek
30 May 2020 //
PHARMABIZ
Health Canada grants market authorization to ROZLYTREK® for ROS1-positive
20 May 2020 //
BLOOMBERG
Health Canada approves Rozlytrek® for NTRK gene fusion-positive solid tumours
28 Apr 2020 //
BLOOMBERG
Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1
21 Feb 2020 //
PRESS PHARMA
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
24 Sep 2019 //
PMLIVE
Entrectinib Receives FDA Approval for Non-Small Cell Lung Cancer
20 Aug 2019 //
PULMONOLOGY
Roche’s tumour-agnostic drug approved by FDA, priced under competitor drug
19 Aug 2019 //
IN-PHARMATECHNOLOGIST
Rozlytrek bags FDA approval
19 Aug 2019 //
PHARMA TIMES
Roche cancer drug the 3rd approved for pan-tumor use
16 Aug 2019 //
BIOPHARMADIVE
FDA approves third oncology drug that targets a key genetic driver of cancer
15 Aug 2019 //
PR NEWSWIRE
Roche scores double approval for new Bayer rival Rozlytrek
15 Aug 2019 //
FIERCE PHARMA
England to fast-track tumour agnostic drugs like Vitrakvi if the price is right
22 Jun 2019 //
PM LIVE
Roche`s Genentech targets cancer cells via video game with Tumor Quest
21 Jun 2019 //
FIERCE PHARMA
Roche fields first approval for Rozlytrek
19 Jun 2019 //
ENDPTS
Roche wins Japan approval for personalized cancer drug Rozlytrek
18 Jun 2019 //
REUTERS
Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1
16 May 2019 //
PRESS RELEASE
Roche’s entrectinib hits the mark in paediatric cancers
16 May 2019 //
PHARMAPHORUM
Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More
28 Sep 2018 //
XCONOMY
Roche to file entrectinib for ROS-1 positive NSCLC
26 Sep 2018 //
PHARMA TIMES
Another Precision Step for Roche as Ignyta Drug Heads to Regulators
25 Sep 2018 //
XCONOMY
Genentech’s TECENTRIQ+Pemetrexed+Pt-Chemo Reduced Disease in Adv`d Lung Cancer
25 Sep 2018 //
BUSINESSWIRE
Regulators Detail Challenges in Defining Orphan Conditions in EU
13 Sep 2018 //
RAPS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.